Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-020-00392-1.pdf
Reference15 articles.
1. Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117–1127 (2010).
2. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366(Mar), 787–798 (2012).
3. Palandri, F. et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk. Res. 74, 86–88 (2018).
4. Al-Ali, H. K. et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br. J. Haematol. 189, 888–903 (2020).
5. Palandri, F. et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126, 1243–1252 (2020).
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights;JCO Precision Oncology;2024-01
2. The management of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-12
3. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease;Expert Review of Clinical Immunology;2023-08-22
4. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety;Journal of Hematology & Oncology;2023-07-27
5. A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases;Current Hematologic Malignancy Reports;2023-07-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3